Last edition
News about "Roche Group"
Astex and Genentech Partner to Develop Precision Small Molecule Therapies for Breast Cancer
Astex Pharmaceuticals has entered into an exclusive global research and licensing agreement with Genentech to advance small molecule therapies for breast cancer. The deal includes a USD 25 million upfront payment to Astex and potential milestone payments exceeding USD 490 million, alongside tiered royalties on future product sales.
Roche Group | 07/07/2026 | By News Bureau
Astex Partners with Genentech on Breast Cancer Therapy Research
Astex has entered an exclusive research and licensing agreement with Genentech for a breast cancer therapy program, with potential deal value exceeding USD 490 million plus tiered royalties.
Roche Group | 07/07/2026 | By News Bureau
Chugai Pharma concludes licence agreement with Roche for CT-388
Chugai Pharmaceutical has signed a licensing deal with F. Hoffmann-La Roche for CT-388, a long-acting GLP-1/GIP receptor agonist for obesity and type-II diabetes, granting Chugai exclusive development and marketing rights in Japan.
Roche Group | 11/10/2025 | By Dineshwori | 671
Genentech Receives Approval from FDA for Alecensa
Genentech, a member of the Roche Group, has announced that the U.S. Food and Drug Administration (FDA) has approved Alecensa (alectinib) for adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer.
Roche Group | 22/04/2024 | By Aishwarya | 754
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy